Other biomarkers, VEGF, MMPs and CD44, have strong prognostic value but demonstrate modest clinical translatability, while EGFR has limited prognostic value but is a promising target as a first-line treatment for advanced HNSCC. Here, VEGFA is linked to head and neck squamous cell carcinoma.